Our group aims to gain a better understanding of the clinical characteristics and mechanisms of progression and therapeutic resistance of hematological tumors with a focus on multiple myeloma and aggressive T and B lymphomas to propose new therapeutic strategies.
The lab is interested in improving the understanding of the molecular mechanisms leading to the progression and therapeutic resistance of multiple myeloma, including extramedullary disease, Hodgkin lymphoma and aggressive non-Hodgkin B and T lymphomas.
To develop these lines of research, we use patient samples and advanced preclinical models for therapeutic, mechanistic and functional studies. We have developed the technology to generate murine models derived from patients by orthotopic implantation (orthotopic PDX) and 2D/3D cultures that we can humanize using components of the human immune system (from the same patient from whom the model has been derived, when possible). Additionally, we are involved in a project that is developing humanized nanomedicines as a new therapeutic strategy for acute myeloid leukemia.
Our group is integrated by professionals from the Clinical Hematology Service of ICO/Hospitalet, the ProCURE/ICO Program and the Pathology Service of the Hospital of Bellvitge. Within the Hematology Service of the ICO Hospitalet, one of our main objectives is to promote translational research training for the professionals of the Service, generating opportunities for the completion of doctoral theses and stimulating new scientific leadership as well as to attract talent with a mixed clinical/researcher profile for the Service.
Group members
Principal Researcher
Principal Researcher
Principal Researcher
Principal Researcher
Principal Researcher
Clinical collaborator
Clinical collaborator
Clinical collaborator
Clinical collaborator
Predoctoral researcher
Posdoctoral researcher
Publications
Bone Marrow Transplant. 2024 Dec 14. doi: 10.1038/s41409-024-02496-9. Online ahead of print. ABSTRACT Central nervous system lymphomas (CNSL) are a heterogeneous group of generally aggressive tumors whose prognosis varies significantly, being more favorable in patients with primary disease and poorer in those with secondary lymphoma. Current treatments typically involve intensive chemotherapy followed by consolidation with […]
Hemasphere. 2024 Dec 10;8(12):e70031. doi: 10.1002/hem3.70031. eCollection 2024 Dec. ABSTRACT This study examines the impact of cytogenetic abnormalities and their co-segregation on the prognosis of newly diagnosed multiple myeloma patients. The analysis included 1304 patients from four different GEM-PETHEMA clinical trials. Genetic alterations, such as t(4;14), t(14;16), del(17p), +1q, and del(1p), were investigated using FISH […]
Hematol Oncol. 2025 Jan;43(1):e70000. doi: 10.1002/hon.70000. ABSTRACT A significant unmet need remains for patients with Hodgkin lymphoma (HL) who fail to respond to first-line treatment or experience an early relapse. Tinostamustine, a novel alkylating deacetylase inhibitor, inhibits tumor cell growth and slows disease progression in models of hematological malignancies and solid tumors. This was a […]
Bone Marrow Transplant. 2024 Nov 22. doi: 10.1038/s41409-024-02459-0. Online ahead of print. ABSTRACT We looked at treatment rates and center density across countries for patients treated in 2022; 46,143 HCTs (19,011 (41.2%) allogeneic, 27,132 (58.8%) autologous) reported by 689 centers. 4329 patients received advanced cellular therapies, 3205 were CAR-T. We found considerable differences in utilization […]
Lancet. 2024 Nov 16;404(10466):1899-1901. doi: 10.1016/S0140-6736(24)02138-X. NO ABSTRACT PMID:39550162 | DOI:10.1016/S0140-6736(24)02138-X
Research Projects
PI21/00684. Improving Outcomes of Patients with Extramedullary Multiple Myeloma. Potential Applicability of Orthoxenograft Models in the Study of Genetic Bases of Drug Resistance. ISCIII/AES. Budget: 135.520,00 euros, 2022 – 2024. PI: Anna Sureda, Co-PI: Lourdes Farre.
201941-30. Humanized nanomedicines selectively killing CXCR4+ cancer cells for Acute Myeloid Leukemia therapy. Marató TV3. Budget: 99.960,81 euros, 2020 – 2024. Projecte coordinat. Sub-projecte PI: Dra. Lourdes Farre
Collaborations
Isolda Casanova. Institut de Recerca del Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Toni Villaverde. Institut de Biotecnologia i de Biomedicina. Universitat Autònoma de Barcelona, Bellaterra, Spain
Sonia Guil. Josep Carreras Leukaemia Research Institute, Badalona, Spain.
Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952
Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069
Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087
Casanovas’ Lab